Mitochondrial dysfunction in diabetic cardiomyopathy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 7, 2011, Pages 1351-1359

  Duncan, Jennifer G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Diabetes; Heart failure; Insulin resistance; Metabolism; Mitochondria; Oxidative stress

Indexed keywords

CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; ENERGY METABOLISM; HEART FAILURE; HEART MUSCLE METABOLISM; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; ENERGY METABOLISM; FATTY ACIDS; HEART; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; OXIDATIVE STRESS; TRIGLYCERIDES;

EID: 79957969004     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.01.014     Document Type: Review

References (128)

1. Engelgau M.M., Geiss L.S., Saaddine J.B., Boyle J.P., Benjamin S.M., Gregg E.W., Tierney E.F., Rios-Burrows N., Mokdad A.H., Ford E.S., Imperatore G., Narayan K.M. The evolving diabetes burden in the United States. Ann. Intern. Med. 2004, 140:945-950.
2. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab. Care 1998, 21:1414-1431.
3. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diab. Care 1993, 16:434-444.
4. S.P.M. Rayner, C. Buckley and V. Press, Coronary heart disease statistics: Diabetes Supplement, in: B.H.F.H.P.R. Group (Ed.), University of Oxford, Oxford, 2001.
5. Abbott R.D., Donahue R.P., Kannel W.B., Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs. women. JAMA 1988, 260:3456-3460.
6. Cohen-Solal A., Beauvais F., Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J. Card. Fail. 2008, 14:615-625.
7. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035-2038.
8. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 1993, 22:6A-13A.
9. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diab. Care 2003, 26:2433-2441.
10. Fein F.S., Sonnenblick E.H. Diabetic cardiomyopathy. Cardiovasc. Drugs Ther. 1994, 8:65-73.
11. Carley A.N., Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta 2005, 1734:112-126.
12. Russell J.C., Proctor S.D. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc. Pathol. 2006, 15:318-330.
13. Bugger H., Abel E.D. Rodent models of diabetic cardiomyopathy. Dis. Model. Mech. 2009, 2:454-466.
14. Lowell B.B., Susulic V., Hamann A., Lawitts J.A., Himms-Hagen J., Boyer B.B., Kozak L.P., Flier J.S. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993, 366:740-742.
15. Kjerrulf M., Berke Z., Aspegren A., Umaerus M., Nilsson T., Svensson L., Hurt-Camejo E. Reduced cholesterol accumulation by leptin deficient (ob/ob) mouse macrophages. Inflamm. Res. 2006, 55:300-309.
16. Wu K.K., Wu T.J., Chin J., Mitnaul L.J., Hernandez M., Cai T.Q., Ren N., Waters M.G., Wright S.D., Cheng K. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 2005, 181:251-259.
17. Aasum E., Belke D.D., Severson D.L., Riemersma R.A., Cooper M., Andreassen M., Larsen T.S. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPARα activator. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H949-H957.
18. Belke D.D., Larsen T.S., Gibbs E.M., Severson D.L. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E1104-E1113.
19. Aasum E., Hafstad A.D., Severson D.L., Larsen T.S. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003, 52:434-441.
20. Yue T.L., Bao W., Gu J.L., Cui J., Tao L., Ma X.L., Ohlstein E.H., Jucker B.M. Rosiglitazone treatment in zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
21. Semeniuk L.M., Kryski A.J., Severson D.L. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H976-H982.
22. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 1997, 34:25-33.
23. Rodrigues B., Cam M.C., McNeill J.H. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 1995, 27:169-179.
24. Banke N.H., Wende A.R., Leone T.C., O'Donnell J.M., Abel E.D., Kelly D.P., Lewandowski E.D. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 2010, 107:233-241.
25. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., Noon G.P., Frazier O.H., Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004, 18:1692-1700.
26. Murthy V.K., Shipp J.C. Accumulation of myocardial triacylglycerols in ketotic diabetes. Diabetes 1977, 26:222-229.
27. Szczepaniak L.S., Victor R.G., Orci L., Unger R.H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 2007, 101:759-767.
28. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamayo P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
29. Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., Miyazaki Y., Kohane I., Costello M., Saccone R., Landaker E.J., Goldfine A.B., Mun E., DeFronzo R., Finlayson J., Kahn C.R., Mandarino L.J. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 2003, 100:8466-8471.
30. Finck B.N., Kelly D.P. PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 2006, 116:615-622.
31. Morino K., Petersen K.F., Dufour S., Befroy D., Frattini J., Shatzkes N., Neschen S., White M.F., Bilz S., Sono S., Pypaert M., Shulman G.I. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J. Clin. Invest. 2005, 115:3587-3593.
32. Petersen K.F., Dufour S., Befroy D., Garcia R., Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. NEJM 2004, 350:664-671.
33. Kelley D.E., He J., Menshikova E.V., Ritov V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
34. Ritov V.B., Menshikova E.V., He J., Ferrell R.E., Goodpaster B.H., Kelley D.E. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005, 54:8-14.
35. Pagel-Langenickel I., Bao J., Joseph J.J., Schwartz D.R., Mantell B.S., Xu X., Raghavachari N., Sack M.N. PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. J. Biol. Chem. 2008, 283:22464-22472.
36. Diamant M., Lamb H.J., Groeneveld Y., Endert E.L., Smit J.W., Bax J.J., Romijn J.A., de Roos A., Radder J.K. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2003, 42:328-335.
37. Rijzewijk L.J., van der Meer R.W., Lamb H.J., de Jong H.W., Lubberink M., Romijn J.A., Bax J.J., de Roos A., Twisk J.W., Heine R.J., Lammertsma A.A., Smit J.W., Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J. Am. Coll. Cardiol. 2009, 54:1524-1532.
38. Scheuermann-Freestone M., Madsen P.L., Manners D., Blamire A.M., Buckingham R.E., Styles P., Radda G.K., Neubauer S., Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040-3046.
39. Anderson E.J., Kypson A.P., Rodriguez E., Anderson C.A., Lehr E.J., Neufer P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol. 2009, 54:1891-1898.
40. Shen X., Zheng S., Thongboonkerd V., Xu M., Pierce W.M., Klein J.B., Epstein P.N. Cardiac mitochondrial damage and biogenesis in a chronic model of type I diabetes. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E896-E905.
41. Kuo T.H., Moore K.H., Giacomelli F., Wiener J. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes 1983, 32:781-787.
42. Boudina S., Sena S., O'Neill B.T., Tathireddy P., Young M.E., Abel E.D. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112:2686-2695.
43. Duncan J.G., Fong J.L., Medeiros D.M., Finck B.N., Kelly D.P. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-α/PGC-1α gene regulatory pathway. Circulation 2007, 115:909-917.
44. Boudina S., Bugger H., Sena S., O'Neill B.T., Zaha V.G., Ilkun O., Wright J.J., Mazumder P.K., Palfreyman E., Tidwell T.J., Theobald H., Khalimonchuk O., Wayment B., Sheng X., Rodnick K.J., Centini R., Chen D., Litwin S.E., Weimer B.E., Abel E.D. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1272-1283.
45. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
46. Buchanan J., Mazumder P.K., Hu P., Chakrabarti G., Roberts M.W., Jeong Yun U., Cooksey R.C., Litwin S.E., Abel E.D. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
47. Mazumder P.K., O'Neill B.T., Roberts M.W., Buchanan J., Yun U.J., Cooksey R.C., Boudina S., Abel E.D. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004, 53:2366-2374.
48. Wang P., Lloyd S.G., Zeng H., Bonen A., Chatham J.C. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2102-H2110.
49. Duncan J.G., Finck B.N. The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res. 2008, 2008:253817.
50. Finck B.N., Kelly D.P. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J. Mol. Cell. Cardiol. 2002, 34:1249-1257.
51. Barger P.M., Kelly D.P. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 2000, 10:238-245.
52. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 1999, 96:7473-7478.
53. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., Gonzalez F.J. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α. J. Biol. Chem. 1998, 273:5678-5684.
54. Campbell F.M., Kozak R., Wagner A., Altarejos J.Y., Dyck J.R., Belke D.D., Severson D.L., Kelly D.P., Lopaschuk G.D. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 2002, 277:4098-4103.
55. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., Gross R.W., Kelly D.P. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl Acad. Sci. USA 2003, 100:1226-1231.
56. Finck B.N. The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7:391-396.
57. Duncan J.G., Bharadwaj K.G., Fong J.L., Mitra R., Sambandam N., Courtois M.R., Lavine K.J., Goldberg I.J., Kelly D.P. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation 2010, 121:426-435.
58. Arany Z., He H., Lin J., Hoyer K., Handschin C., Toka O., Ahmad F., Matsui T., Chin S., Wu P.H., Rybkin, Shelton J.M., Manieri M., Cinti S., Schoen F.J., Bassel-Duby R., Rosenzweig A., Ingwall J.S., Spiegelman B.M. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005, 1:259-271.
59. Kjekshus J.K., Mjos O.D. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J. Clin. Invest. 1972, 51:1767-1776.
60. Mjos O.D. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J. Clin. Invest. 1971, 50:1386-1389.
61. Boudina S., Sena S., Theobald H., Sheng X., Wright J.J., Hu X.X., Aziz S., Johnson J.I., Bugger H., Zaha V.G., Abel E.D. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56:2457-2466.
62. How O.J., Aasum E., Severson D.L., Chan W.Y., Essop M.F., Larsen T.S. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006, 55:466-473.
63. Peterson L.R., Herrero P., Schechtman K.B., Racette S.B., Waggoner A.D., Kisrieva-Ware Z., Dence C., Klein S., Marsala J., Meyer T., Gropler R.J. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
64. Skulachev V.P. Uncoupling: new approaches to an old problem of bioenergetics. Biochim. Biophys. Acta 1998, 1363:100-124.
65. Ledesma A., de Lacoba M.G., Rial E. The mitochondrial uncoupling proteins. Genome Biol. 2002, 3. REVIEWS3015.
66. Fleury C., Neverova M., Collins S., Raimbault S., Champigny O., Levi-Meyrueis C., Bouillaud F., Seldin M.F., Surwit R.S., Ricquier D., Warden C.H. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 1997, 15:269-272.
67. Gimeno R.E., Dembski M., Weng X., Deng N., Shyjan A.W., Gimeno C.J., Iris F., Ellis S.J., Woolf E.A., Tartaglia L.A. Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 1997, 46:900-906.
68. Stuart J.A., Brindle K.M., Harper J.A., Brand M.D. Mitochondrial proton leak and the uncoupling proteins. J. Bioenerg. Biomembr. 1999, 31:517-525.
69. Brand M.D., Esteves T.C. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005, 2:85-93.
70. Murray A.J., Anderson R.E., Watson G.C., Radda G.K., Clarke K. Uncoupling proteins in human heart. Lancet 2004, 364:1786-1788.
71. Murray A.J., Panagia M., Hauton D., Gibbons G.F., Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005, 54:3496-3502.
72. Conn P.M. Handbook of Models of Human Aging 2006, Elsevier Academic Press. First ed.
73. Raha S., Robinson B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 2000, 25:502-508.
74. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.
75. Coughlan M.T., Thorburn D.R., Penfold S.A., Laskowski A., Harcourt B.E., Sourris K.C., Tan A.L., Fukami K., Thallas-Bonke V., Nawroth P.P., Brownlee M., Bierhaus A., Cooper M.E., Forbes J.M. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009, 20:742-752.
76. Li L., Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006, 55:1516-1523.
77. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 2006, 91:807-819.
78. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992, 256:628-632.
79. Turko I.V., Li L., Aulak K.S., Stuehr D.J., Chang J.Y., Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J. Biol. Chem. 2003, 278:33972-33977.
80. Andreyev A.Y., Kushnareva Y.E., Starkov A.A. Mitochondrial metabolism of reactive oxygen species. Biochem. Mosc. 2005, 70:200-214.
81. Ji L.L. Antioxidants and oxidative stress in exercise. Proc. Soc. Exp. Biol. Med. 1999, 222:283-292.
82. Mari M., Morales A., Colell A., Garcia-Ruiz C., Fernandez-Checa J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 2009, 11:2685-2700.
83. Johnson D.T., Harris R.A., French S., Aponte A., Balaban R.S. Proteomic changes associated with diabetes in the BB-DP rat. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E422-E432.
84. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5:561-568.
85. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 2003, 52:1-8.
86. Kim J.S., Jin Y., Lemasters J.J. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2024-H2034.
87. Willemsen S., Hartog J.W., Hummel Y.M., van Ruijven M.H., van der Horst I.C., van Veldhuisen D.J., Voors A.A. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur. J. Heart Fail. 2011, 13:76-82.
88. Bhamra G.S., Hausenloy D.J., Davidson S.M., Carr R.D., Paiva M., Wynne A.M., Mocanu M.M., Yellon D.M. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res. Cardiol. 2008, 103:274-284.
89. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
90. Giardino I., Edelstein D., Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J. Clin. Invest. 1996, 97:1422-1428.
91. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001, 108:1341-1348.
92. Du X.L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl Acad. Sci. USA 2000, 97:12222-12226.
93. Frustaci A., Kajstura J., Chimenti C., Jakoniuk I., Leri A., Maseri A., Nadal-Ginard B., Anversa P. Myocardial cell death in human diabetes. Circ. Res. 2000, 87:1123-1132.
94. Cai L., Wang J., Li Y., Sun X., Wang L., Zhou Z., Kang Y.J. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005, 54:1829-1837.
95. Ye G., Metreveli N.S., Ren J., Epstein P.N. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003, 52:777-783.
96. Ye G., Metreveli N.S., Donthi R.V., Xia S., Xu M., Carlson E.C., Epstein P.N. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004, 53:1336-1343.
97. Shen X., Zheng S., Metreveli N.S., Epstein P.N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798-805.
98. Szabadkai G., Duchen M.R. Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) 2008, 23:84-94.
99. Duchen M.R. Roles of mitochondria in health and disease. Diabetes 2004, 53(Suppl 1):S96-S102.
100. Parekh A.B. Store-operated Ca2+ entry: dynamic interplay between endoplasmic reticulum, mitochondria and plasma membrane. J. Physiol. 2003, 547:333-348.
101. Bianchi K., Vandecasteele G., Carli C., Romagnoli A., Szabadkai G., Rizzuto R. Regulation of Ca2+ signalling and Ca2+-mediated cell death by the transcriptional coactivator PGC-1alpha. Cell Death Differ. 2006, 13:586-596.
102. Fauconnier J., Lanner J.T., Zhang S.J., Tavi P., Bruton J.D., Katz A., Westerblad H. Insulin and inositol 1, 4, 5-trisphosphate trigger abnormal cytosolic Ca2+ transients and reveal mitochondrial Ca2+ handling defects in cardiomyocytes of ob/ob mice. Diabetes 2005, 54:2375-2381.
103. Belke D.D., Swanson E.A., Dillmann W.H. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004, 53:3201-3208.
104. Flarsheim C.E., Grupp I.L., Matlib M.A. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am. J. Physiol. 1996, 271:H192-H202.
105. Oliveira P.J., Seica R., Coxito P.M., Rolo A.P., Palmeira C.M., Santos M.S., Moreno A.J. Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett. 2003, 554:511-514.
106. Barouch L.A., Gao D., Chen L., Miller K.L., Xu W., Phan A.C., Kittleson M.M., Minhas K.M., Berkowitz D.E., Wei C., Hare J.M. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ. Res. 2006, 98:119-124.
107. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51:1938-1948.
108. Li Z., Zhang T., Dai H., Liu G., Wang H., Sun Y., Zhang Y., Ge Z. Involvement of endoplasmic reticulum stress in myocardial apoptosis of streptozocin-induced diabetic rats. J. Clin. Biochem. Nutr. 2007, 41:58-67.
109. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., Kang Y.J. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48:1688-1697.
110. Williamson C.L., Dabkowski E.R., Baseler W.A., Croston T.L., Alway S.E., Hollander J.M. Enhanced apoptotic propensity in diabetic cardiac mitochondria: influence of subcellular spatial location. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H633-H642.
111. Dabkowski E.R., Baseler W.A., Williamson C.L., Powell M., Razunguzwa T.T., Frisbee J.C., Hollander J.M. Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H529-H540.
112. Dabkowski E.R., Williamson C.L., Bukowski V.C., Chapman R.S., Leonard S.S., Peer C.J., Callery P.S., Hollander J.M. Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H359-H369.
113. Boudina S., Abel E.D. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 2006, 21:250-258.
114. Karbowski M., Youle R.J. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 2003, 10:870-880.
115. Youle R.J., Karbowski M. Mitochondrial fission in apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6:657-663.
116. Dlaskova A., Spacek T., Santorova J., Plecita-Hlavata L., Berkova Z., Saudek F., Lessard M., Bewersdorf J., Jezek P. 4Pi microscopy reveals an impaired three-dimensional mitochondrial network of pancreatic islet beta-cells, an experimental model of type-2 diabetes. Biochim. Biophys. Acta 2010, 1797:1327-1341.
117. Molina A.J., Wikstrom J.D., Stiles L., Las G., Mohamed H., Elorza A., Walzer G., Twig G., Katz S., Corkey B.E., Shirihai O.S. Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. Diabetes 2009, 58:2303-2315.
118. Bach D., Pich S., Soriano F.X., Vega N., Baumgartner B., Oriola J., Daugaard J.R., Lloberas J., Camps M., Zierath J.R., Rabasa-Lhoret R., Wallberg-Henriksson H., Laville M., Palacin M., Vidal H., Rivera F., Brand M., Zorzano A. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J. Biol. Chem. 2003, 278:17190-17197.
119. Yu T., Sheu S.S., Robotham J.L., Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc. Res. 2008, 79:341-351.
120. Paradies G., Petrosillo G., Paradies V., Ruggiero F.M. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium 2009, 45:643-650.
121. Hoch F.L. Cardiolipins and biomembrane function. Biochim. Biophys. Acta 1992, 1113:71-133.
122. Houtkooper R.H., Vaz F.M. Cardiolipin, the heart of mitochondrial metabolism. Cell. Mol. Life Sci. 2008, 65:2493-2506.
123. Robinson N.C. Functional binding of cardiolipin to cytochrome c oxidase. J. Bioenerg. Biomembr. 1993, 25:153-163.
124. Ardail D., Lerme F., Louisot P. Further characterization of mitochondrial contact sites: effect of short-chain alcohols on membrane fluidity and activity. Biochem. Biophys. Res. Commun. 1990, 173:878-885.
125. Fry M., Green D.E. Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J. Biol. Chem. 1981, 256:1874-1880.
126. Hauff K.D., Hatch G.M. Cardiolipin metabolism and Barth syndrome. Prog. Lipid Res. 2006, 45:91-101.
127. Chicco A.J., Sparagna G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 2007, 292:C33-C44.
128. Han X., Yang J., Cheng H., Yang K., Abendschein D.R., Gross R.W. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry 2005, 44:16684-16694.